Individual and bivalent vaccines against botulinum neurotoxin serotypes A and B using DNA-based Semliki Forest virus vectors.
We evaluated individual and bivalent replicon vaccines against Clostridiumbotulinum neurotoxin serotypes A (BoNT/A) or B (BoNT/B). The DNA replicon vaccine (pSCARSBHc) encoding the Hc domain of BoNT/B (BHc) induced better responses and protection against BoNT/B mouse challenge than conventional DNA vaccine. The dual-expressing DNA vaccine (pSCARSA/BHc) protected similarly to a DNA replicon vaccine mixture (pSCARSAHc+pSCARSBHc). Additionally, recombinant SFV particles, VRP-AHc or VRP-BHc, protected mice from high-dose BoNT/A or BoNT/B challenge, respectively. Mice given either dual-expressing VRP-A/BHc or mixture of VRP-AHc and VRP-BHc were protected from challenge with serotype A/B mixtures. These data justify further testing in other animals or humans.
Yu
Yunzhou
Y
Beijing Institute of Biotechnology, 20 Dong Dajie Street, Fengtai District, Beijing 100071, China.
Yu
Jiyu
J
Li
Na
N
Wang
Shuang
S
Yu
Weiyuan
W
Sun
Zhiwei
Z
D000818:Animals; D000907:Antibodies, Bacterial / Q000097:blood; D001428:Bacterial Vaccines / Q000235:genetics / Q000276:immunology*; D001905:Botulinum Toxins / Q000235:genetics / Q000276:immunology*; D019274:Botulinum Toxins, Type A / Q000235:genetics / Q000276:immunology*; D001906:Botulism / Q000276:immunology / Q000517:prevention & control*; D003014:Clostridium botulinum / Q000276:immunology; D005260:Female; D051379:Mice; D008807:Mice, Inbred BALB C; D012093:Replicon; D012672:Semliki forest virus / Q000276:immunology; D019444:Vaccines, DNA / Q000235:genetics / Q000276:immunology
D000907:Antibodies, Bacterial; D001428:Bacterial Vaccines; D019444:Vaccines, DNA; C096323:rimabotulinumtoxinB; D001905:Botulinum Toxins; D019274:Botulinum Toxins, Type A